Updated:
Blackrock Neurotech
Implantable brain technology changing lives. | Blackrock Neurotech is a team of the world’s leading engineers, neuroscientists, and visionaries.
Blackrock Neurotech
Implantable brain technology changing lives. | Blackrock Neurotech is a team of the world’s leading engineers, neuroscientists, and visionaries. Our mission is simple: We want people with neurological disorders to walk, talk, see, hear, and feel again. We’re engineering the next generation of neural implants, including implantable brain-computer interface technology that restores function and independence to individuals with neurological disorders.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Salt Lake City
Corporate office
630 Komas Drive, Suite 200, Salt Lake City, UT 84108, United States
Principals
Marcus Gerhardt
Co-Founder & CEO
Florian Solzbacher
Co-Founder & CSO
Christian Angermayer
Co-Chairman
Tim Sievers
Co-Chairman
Thomas Thiele
CFO
Sector focus
Frequently asked questions
Who runs investment decisions at Blackrock Neurotech?
Marcus Gerhardt serves as CEO. The board is co-chaired by Christian Angermayer, founder of Apeiron Investment Group, and Tim Sievers, founder of Deposit Solutions. Strategic direction involves both executive leadership and academic co-founder Florian Solzbacher (per the firm's website).
How does Blackrock Neurotech source its technology and IP?
The core technology originates from research at the University of Utah, where co-founder Florian Solzbacher holds a chaired professorship. The firm has licensed or transferred university-developed patents into a commercial platform, typical of university spinouts in the neurotechnology space.
Is Blackrock Neurotech a single family office or does it operate more like a venture firm?
Blackrock Neurotech is a private operating company developing medical devices, not a family office or asset manager. Its capital structure is opaque, but its governance includes a board co-chaired by Christian Angermayer, whose family office Apeiron Investment Group frequently backs deep tech companies.
Does Blackrock Neurotech accept outside capital or only rely on internal funding?
The firm does not publicly disclose its capital sources. Its website lists no funds or investment vehicles for external investors. Given the capital-intensive nature of medical device development, undisclosed private funding rounds or grants are likely.
What investment stages does Blackrock Neurotech typically target?
The firm does not invest in external companies — it is an operating company that develops and commercializes its own neurotechnology products. Its stage focus is on clinical and commercial deployment rather than external portfolio building.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: